CPHI [CHINA PHARMA] 10-K: (Original Filing)

[FORM 10-K x For the fiscal year ended December 31, 2013 or ¨ For the transition period from _________ to _____________ China Pharma Holdings, Inc. Nevada 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Title of each class Name of each] [Re: Service about being independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Yingwen Zhang, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Baowen Dong, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an] [Loans Extension Agreement Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD30,667 respectively as of December 31, 2013. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay the loans, both Ms. Tsui and] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 20, 2014 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the year ended December 31, 2013 appearing] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 13, 2013 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the year ended December 31, 2012 appearing] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 20, 2014 President and Chief Executive Officer EX-32.1 10 ex321.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 20, 2014 (principal financial officer and principal accounting officer) EX-32.2 11 ex322.htm]

By | 2016-03-28T19:41:44+00:00 March 20th, 2014|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-K: FORM 10-K x For the fiscal year ended

[FORM 10-K x For the fiscal year ended December 31, 2013 or ¨ For the transition period from _________ to _____________ China Pharma Holdings, Inc. Nevada 73-1564807 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 (011) 86 898-6681-1730 Title of each class Name of each] [Re: Service about being independent director, Chairman of the Nominating and Compensation Committee, and member of the Audit Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Yingwen Zhang, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, member of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Baowen Dong, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an independent] [Re: Service about being independent director, chairman of the Audit Committee, and member of the Nominating and Compensation Committee of China Pharma Holdings, Inc. December 19, 2013 Dear Mr. Gene Michael Bennett, On behalf of the Board of Directions and the Company, I am pleased to welcome you to join the Board of the China Pharma Holdings, Inc. as an] [Loans Extension Agreement Reference is made to the loans from Ms. Heung Mei Tsui to China Pharma Holdings, Inc. (the “Company”), the principal and accumulated interest totaled USD1,354,567 and USD30,667 respectively as of December 31, 2013. Due to the fact the Company temporarily did not have enough balance in its oversea account to repay the loans, both Ms. Tsui and] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 20, 2014 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the year ended December 31, 2013 appearing] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in Registration Statement No. 333-141734 Post-Effective Amendment No. 1 to Form SB-2 on Form S-3 of our report dated March 13, 2013 relating to the consolidated financial statements of China Pharma Holdings, Inc. and subsidiaries as of and for the year ended December 31, 2012 appearing] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-K of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 20, 2014 President and Chief Executive Officer EX-32.1 10 ex321.htm] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: March 20, 2014 (principal financial officer and principal accounting officer) EX-32.2 11 ex322.htm]

By | 2016-03-28T19:42:50+00:00 March 20th, 2014|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments
Read More

TPI [TIANYIN PHARMACEUTICAL] DEF 14A: (Original Filing)

[SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT x o Check the appropriate box: o o x o o Tianyin Pharmaceutical Co., Inc. Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies: Common Stock o (2) Aggregate number of securities to which transaction applies: (3) Per unit price]

By | 2016-03-19T15:49:28+00:00 March 18th, 2014|Categories: Chinese Stocks, SEC Original, TPI|Tags: , , , , , |0 Comments
Read More

TPI [TIANYIN PHARMACEUTICAL] DEF 14A: SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT

[SCHEDULE 14A INFORMATION INFORMATION REQUIRED IN PROXY STATEMENT x o Check the appropriate box: o o x o o Tianyin Pharmaceutical Co., Inc. Payment of Filing Fee (Check the appropriate box): x o (1) Title of each class of securities to which transaction applies: Common Stock o (2) Aggregate number of securities to which transaction applies: (3) Per unit price]

By | 2016-03-19T15:51:26+00:00 March 18th, 2014|Categories: Chinese Stocks, TPI, Webplus ver|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)

[EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company believes that Executive provides unique advisory and management services for the Company and wishes to retain the continued services of Executive as its Chief Executive Officer; and WHEREAS, the Company and Executive have reached an understanding with respect to Executive’s continuing employment with the Company for a] [EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company desires to employ Executive as its Chief Financial Officer on the terms and conditions as set forth hereinafter, and Executive desires to be so employed; NOW, THEREFORE, IN CONSIDERATION of the foregoing facts, the mutual covenants and agreements contained herein and other good and valuable consideration, the] []

By | 2016-03-27T16:19:31+00:00 March 13th, 2014|Categories: Chinese Stocks, SEC Original, SKBI|Tags: , , , , , |0 Comments
Read More

SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT

[EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company believes that Executive provides unique advisory and management services for the Company and wishes to retain the continued services of Executive as its Chief Executive Officer; and WHEREAS, the Company and Executive have reached an understanding with respect to Executive’s continuing employment with the Company for a] [EMPLOYMENT AGREEMENT Agreement Executive Company This EMPLOYMENT AGREEMENT (this “ WHEREAS, the Company desires to employ Executive as its Chief Financial Officer on the terms and conditions as set forth hereinafter, and Executive desires to be so employed; NOW, THEREFORE, IN CONSIDERATION of the foregoing facts, the mutual covenants and agreements contained herein and other good and valuable consideration, the] []

By | 2016-03-27T16:21:01+00:00 March 13th, 2014|Categories: Chinese Stocks, SKBI, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] 424B5: (Original Filing)

[Prospectus Supplement To Prospectus Dated December 31, 2013 Registration No. 333-192963 Biostar Pharmaceuticals, Inc. 1,650,000 shares of common stock Our shares of common stock are currently traded on the Nasdaq Capital Market under the symbol “BSPM.” On March 7, 2014, the closing sale price of our shares of common stock was $2.97 per share. Risk Factors Investing in our securities]

By | 2016-03-28T18:37:11+00:00 March 10th, 2014|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] 424B5: Prospectus Supplement To Prospectus Dated December 31, 2013

[Prospectus Supplement To Prospectus Dated December 31, 2013 Registration No. 333-192963 Biostar Pharmaceuticals, Inc. 1,650,000 shares of common stock Our shares of common stock are currently traded on the Nasdaq Capital Market under the symbol “BSPM.” On March 7, 2014, the closing sale price of our shares of common stock was $2.97 per share. Risk Factors Investing in our securities]

By | 2016-03-28T18:38:43+00:00 March 10th, 2014|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] 8-K: (Original Filing)

[CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC. 208 Summitrail Lane Dawsonville, GA 30524 Phone (770) 815-0885 Mr. Ronghua Wang Chairman and CEO Biostar Pharmaceuticals, Inc No. 588 Shiji Xi Avenue Xianyang, 712046 Phone: 86 29 3368 6638 Dear Mr. Wang: “ Moody Capital Solutions, Inc. Axiom Capital Management, Inc Biostar Pharmaceuticals, Inc. This letter (the The terms of such] [BIOSTAR PHARMACEUTICALS, INC. Issuance Date Date of Issuance: March [___], 2014 (“ Company Holder 1 16 Securities Purchase Agreement Biostar Pharmaceuticals, Inc., a Maryland corporation (the “ 1. (a) Mechanics of Exercise 1 (f) Exercise Notice Aggregate Exercise Price 1 (d) st . Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1] [March 10, 2014 Board of Directors Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People’s Republic of China 712046 Company Shares Shares Shares Securities Purchase Agreement Registration Statement Commission Act Base Prospectus Prospectus Supplement Prospectus Schiff Hardin LLP EX-5.1 4 ex5-1.htm EX-5.1] [SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT Agreement Company Buyer Buyers This RECITALS Registration Statement 1933 Act SEC Common Shares Common Stock B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms stated in this Agreement, (i) the aggregate number of shares of Common Stock (as defined below) set forth opposite such Buyer’s name in column] [Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1 million. The net proceeds from this offering will be used for working capital and other general corporate purposes. The completion of the offering will occur on or before March 13, 2014. Moody Capital Solutions, Inc.] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): March 10, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T18:40:05+00:00 March 10th, 2014|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] 8-K: CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC.

[CONFIDENTIAL March 1, 2014 MOODY CAPITAL SOLUTIONS, INC. 208 Summitrail Lane Dawsonville, GA 30524 Phone (770) 815-0885 Mr. Ronghua Wang Chairman and CEO Biostar Pharmaceuticals, Inc No. 588 Shiji Xi Avenue Xianyang, 712046 Phone: 86 29 3368 6638 Dear Mr. Wang: “ Moody Capital Solutions, Inc. Axiom Capital Management, Inc Biostar Pharmaceuticals, Inc. This letter (the The terms of such] [BIOSTAR PHARMACEUTICALS, INC. Issuance Date Date of Issuance: March [___], 2014 (“ Company Holder 1 16 Securities Purchase Agreement Biostar Pharmaceuticals, Inc., a Maryland corporation (the “ 1. (a) Mechanics of Exercise 1 (f) Exercise Notice Aggregate Exercise Price 1 (d) st . Subject to the terms and conditions hereof (including, without limitation, the limitations set forth in Section 1] [March 10, 2014 Board of Directors Biostar Pharmaceuticals, Inc. No. 588 Shiji Avenue Xiangyang City, Shaanxi Province People’s Republic of China 712046 Company Shares Shares Shares Securities Purchase Agreement Registration Statement Commission Act Base Prospectus Prospectus Supplement Prospectus Schiff Hardin LLP EX-5.1 4 ex5-1.htm EX-5.1] [SECURITIES PURCHASE AGREEMENT SECURITIES PURCHASE AGREEMENT Agreement Company Buyer Buyers This RECITALS Registration Statement 1933 Act SEC Common Shares Common Stock B. Each Buyer wishes to purchase, and the Company wishes to sell, upon the terms stated in this Agreement, (i) the aggregate number of shares of Common Stock (as defined below) set forth opposite such Buyer’s name in column] [Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, are expected to be approximately $4.1 million. The net proceeds from this offering will be used for working capital and other general corporate purposes. The completion of the offering will occur on or before March 13, 2014. Moody Capital Solutions, Inc.] [FORM 8-K CURRENT REPORT Date of Report (Date of earliest event reported): March 10, 2014 BIOSTAR PHARMACEUTICALS, INC. Maryland 001-34708 20-8747899 (State or Other Jurisdiction (Commission (I.R.S. Employer of Incorporation) Identification No.) No. 588 Shiji Avenue Xiangyang City, Shaanxi Province, People’s Republic of China 712046 86-029-33686638 N/A (Former name or former address, if changed since last report) ¨ ¨ ¨]

By | 2016-03-28T18:41:02+00:00 March 10th, 2014|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More
Skip to toolbar